Table 5 Prevalence of MTB detection by both Xpert MTB/RIF and PowerChek™ MTB/NTM Real-Time PCR assays, within groups with specific lung pathologies
From: Burden of respiratory tract infections at post mortem in Zambian children
| Xpert MTB/RIF Assay | PowerChek™ MTB/NTM Assaya | ||
|---|---|---|---|
| MTB detected | MTB detected | NTM detected | |
| Overall | 30 % (36/121) | 16 % (12/73) | 62 % (45/73) |
| Lung pathology | |||
| Bronchopneumonia | 30 % (18b/60) | 9 % (3/35) | 63 % (22/35) |
| Interstitial pneumonitis | 60 % (8/20) | 17 % (2/12) | 67 % (8/12) |
| Tuberculosis (All forms) (PTB and/or EPTB) | 30 % (3/10) | 67 % (6/9) | 22 % (2/9) |
| EPTB | 100 % (1/1) | 100 % (1/1) | 0 % (0/1) |
| PTB | 22 % (2/9) | 63 % (5/8) | 20 % (2/8) |
| Cytomegalovirus pneumonia | 13 % (1/8) | 0 % (0/4) | 75 % (3/4) |
| Pneumocystis Jirovecii pneumonia | 17 % (1/5) | 0 % (0/3) | 67 % (2/3) |
| Pulmonary oedema | 33 % (2/6) | 20 % (1/5) | 80 % (4/5) |
| Candidiasis | 0 % (0/3) | 0 % (0/2) | 50 % (1/2) |
| Acute respiratory distress | 0 % (0/1) | 0 % (0/1) | 100 % (1/1) |
| Normal lungs | 20 % (2/10) | 0 % (0/7) | 72 % (5/7) |